Clinical trial

Gilteritinib for the Treatment of ALK NSCLC

NCT06225427

StatusRECRUITING

Study typeINTERVENTIONAL

Start date2024-07-25

PhasePHASE1

Study timeline

Study start (actual)2024-07-25Date precision: day

Registry last updated2026-06-26

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Lung Non-Small Cell Carcinomaunresolved

Stage IV Lung Cancer AJCC v8unresolved

Interventions

BiopsyPROCEDURE

Biospecimen CollectionPROCEDURE

Computed TomographyPROCEDURE

EchocardiographyPROCEDURE

GilteritinibDRUG · verified · RxNorm: gilteritinib

Magnetic Resonance ImagingPROCEDURE

Questionnaire AdministrationOTHER

Sponsors & collaborators

University of Michigan Rogel Cancer Centerlead sponsor

Mapped research locations

Los AngelesCalifornia, United States1 Washington D.C.District of Columbia, United States1 Ann ArborMichigan, United States1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT06225427 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.